Revolutionary Liposomal Formulation Technology
Our proprietary technology harnesses the power of liposomal formulations, delivering stability and efficacy in both oral and intravenous treatments.
J & D Pharmaceuticals LLC Receives Orphan Drug Designation for Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
This is a carousel outlining featured items. Navigate using the arrow buttons.
Combining two molecules of salicylic acid and adding liposomal technology is our revolutionary advantage over all current analgesics.
Our proprietary technology harnesses the power of liposomal formulations, delivering stability and efficacy in both oral and intravenous treatments.
Discover how our innovative solution offers a safer and more effective treatment for rare and serious diseases/conditions.
To discover, rediscover, develop, and deliver safe, novel, and effective treatments that assist patients and doctors in conquering rare and serious diseases/conditions.
